RPRX Earnings & Financial Statements
Royalty Pharma plc
$58.99
+$2.42(+4.28%)
62
Overall
100
Value
36
Tech
52
Quality
Market Cap
$33.92B
Volume
2.76M
52W Range
$35.23 - $64.38
Target Price
$66.00
RPRX earnings and financial statements: Royalty Pharma plc's income statement, balance sheet and cash flow statement, annual and quarterly.
RPRX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B |
| Operating income | $1.56B | $1.29B | $1.49B | $307.06M | $1.43B |
| EBITDA | $1.63B | $1.56B | $1.89B | $418.02M | $1.43B |
| Net income | $770.95M | $858.98M | $1.13B | $42.83M | $619.73M |
| EPS (diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B |
| Shareholders’ equity | $6.48B | $6.95B | $6.53B | $5.63B | $5.78B |
| Cash and equivalents | $618.70M | $929.03M | $477.01M | $1.71B | $1.54B |
| Long-term debt | $8.57B | $6.61B | $6.14B | $6.12B | $7.10B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| Free cash flow | $2.49B | $2.77B | $2.99B | $2.14B | $2.02B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | RPRX | $58.99 | +4.3% | 2.76M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |